12:00 AM
Feb 09, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Avastin bevacizumab regulatory update

The U.K.'s NICE issued a final appraisal document (FAD) recommending the use of Sutent sunitinib from Pfizer as a first-line treatment for advanced and/or metastatic renal cell carcinoma (RCC). The agency said Pfizer also agreed to a patient access scheme with the Department of Health, in...

Read the full 208 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >